文献速递白血病淋巴瘤

LIN28B 是人胎儿 B 淋巴细胞生成及 KMT2A::AFF1 婴儿白血病起始的关键

LIN28B is essential for human fetal B-lymphopoiesis and initiation of KMT2A::AFF1 infant leukemia.
PubMed 文献 · Blood · 2026-01-01

本研究通过比较人胎儿与成人造血干/祖细胞转录组,获得胎儿发育特异性基因特征,LIN28B 及其下游效应分子位列前茅且在婴儿 ALL 中表达。功能实验显示 LIN28B 维持人胎肝 CD34+ 细胞增殖与干样特性并支持 B 细胞及 NK 细胞淋巴生成;在人胎肝来源 CRISPR-KMT2A::AFF1 模型中,缺失 LIN28B 时 KMT2A::AFF1 易位不能转化细胞,而表达 LIN28B 的白血病在体外和体内增殖更强。

要点

  • LIN28B 维持人胎肝 CD34+ 细胞增殖、干样特性及 B/NK 细胞淋巴生成。
  • 缺失 LIN28B 时 KMT2A::AFF1 易位不能转化人胎肝 CD34+ 细胞。
  • LIN28B 表达增强 KMT2A::AFF1 白血病体外和体内增殖,敲低后优势丧失。

核心结论

  • LIN28B 在人胎儿 B 淋巴细胞生成中必需,且是 KMT2A::AFF1 婴儿 ALL 起始所需,其活性促进该白血病侵袭性行为,是表达 LIN28B 白血病的潜在靶点。

研究设计与样本

  • 研究采用分子、功能及体内实验,比较人胎儿与成人造血干/祖细胞转录组,并在人胎肝来源 CRISPR-CRISPR 相关蛋白 9 KMT2A::AFF1 模型中验证。

主要发现

  • 人胎儿与成人 HSPC 转录组比较得到胎儿发育特异性基因特征,LIN28B 及其下游效应分子位列前茅并在 iALL 中表达。
  • LIN28B 在人胎肝 CD34+ 细胞中维持增殖和干样特性,支持 B 细胞与自然杀伤细胞淋巴生成。
  • CRISPR-KMT2A::AFF1 模型中缺失 LIN28B 时人胎肝 CD34+ 细胞不能转化。
  • 表达 LIN28B 的 CRISPR-KMT2A::AFF1 白血病体外和体内增殖更强,敲低 LIN28B 后该优势丧失。
  • 机制上 LIN28B 稳定关键早期 B 淋巴系基因、表观遗传调控因子及细胞周期和抗凋亡基因。

临床怎么用

  • LIN28B 表达可作为 KMT2A::AFF1 婴儿 ALL 的潜在治疗靶点,尤其在不伴协同突变的情况下。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Infant acute lymphoblastic leukemia (iALL) is initiated in utero, most often by rearrangements of the KMT2A gene (KMT2Ar). It carries a very poor prognosis despite a lack of additional oncogenic driver mutations common in childhood ALL. Here, we aimed to identify specific properties of human fetal hematopoietic stem/progenitor cells (HSPC) that promote leukemic transformation in KMT2Ar iALL using molecular, functional, and in vivo assays. Through comparison of human fetal HSPC with adult HSPC transcriptomes we derived a fetal development-specific gene signature and identified the fetal oncogene LIN28B and its downstream effectors among the top hits. These genes were also expressed in iALL. Functional assays revealed that LIN28B was essential in normal human fetal liver (FL) CD34+ cells to maintain proliferation and stem-like properties, and support B-cell and natural killer cell lymphopoiesis. To interrogate the role of LIN28B in iALL, we used a human FL-derived CRISPR-CRISPR-associated protein 9 KMT2A::AFF1 model. In this CRISPRKMT2A::AFF1 model, human FL CD34+ cells fail to transform upon induction of KMT2A::AFF1 translocation in the absence of LIN28B. Furthermore, LIN28B-expressing CRISPRKMT2A::AFF1 leukemias were more proliferative in vitro and in vivo, with this advantage being lost upon LIN28B knockdown. Mechanistic studies showed that LIN28B acts by stabilizing key early B-lymphoid genes, epigenetic regulators, and cell cycle and antiapoptotic genes. Thus, LIN28B has an essential role in normal human fetal B-lymphopoiesis and is necessary for initiation of KMT2A::AFF1 iALL in human fetal cells in the absence of cooperating mutations. LIN28B activity contributes to the aggressive behavior of KMT2A::AFF1 ALL, making it an attractive target in LIN28B-expressing leukemias.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Ling RE, Welsh AMN, Hamer L, et al. LIN28B is essential for human fetal B-lymphopoiesis and initiation of KMT2A::AFF1 infant leukemia. Blood. 2026. PMID: 42213620. doi:10.1182/blood.2025028877

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。